Drug intelligence / Profile preview

DWC202203

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWC202203 is a drug candidate currently under investigation in clinical trials for potential drug-drug interactions, specifically in combination with other investigational agents such as DWP14012 and DWC202202. The available information does not specify the mechanism of action, primary indication, or therapeutic class for DWC202203. It is being developed by Daewoong Pharmaceutical Co., LTD., and has been included in phase 1 clinical trials to assess its pharmacokinetics and pharmacodynamics when co-administered with other drugs[1][2][6].

Beyond the preview

Go deeper on DWC202203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC202203.

Explore the full profile